giving must be an acceleration of giving workers more control over how they do their errands, as long as they do their hours and all the study show particularly with women workers that if you give workers flexibility and you give them a bit of control you treat them like grown ups, there are actually more productive and they work for longer and they do more. they get more done. and so, i think they do embrace this and i think you ll be a very progressive step but it s going to be a choice. some people want to come to the office and other people will want to do more at home. it s about giving people a choice. we more at home. it s about giving people a choice. more at home. it s about giving people a choice. we shall see. let us move on- vaccine hubs in schools if children are offered jabs. if is the work there because it s by no means the under 18 will be offered the jabs but according to the eye, people could be vaccinated in their own schools to boost uptake if uk
must be an acceleration of giving workers more control over how they do their errands, as long as they do their hours and all the study show particularly with women workers that if you give workers flexibility and you give them a bit of control you treat them like grown ups, there are actually more productive and they work for longer and they do more. they get more done. and so, i think they do embrace this and i think you ll be a very progressive step but it s going to be a choice. some people want to come to the office and other people will want to do more at home. it s about giving people a choice. we more at home. it s about giving people a choice. more at home. it s about giving people a choice. we shall see. let us move on- vaccine hubs in schools if children are offered jabs. if is the work there because it s by no means the under 18 will be offered the jabs but according to the eye, people could be vaccinated in their own schools to boost uptake if uk
so one of the sorriest parts of the story on the drug industry in general, but the story part in particular on opioids is the fda. and it s not that they are complicit in terms of sitting there and taking a bundle of money over the table and saying okay, we are going to do this. they just weren t very effective regulators. and that comes from approved oxycontin. in other words, purdue went to them and said we would like a couple of things on the label. we would like on the label that the odds of addiction are very rare because this is a time release formula. and we believe that the study show that there is something to that. the fda had no studies. there was no proof of that. purdue had done no eddies of that but the fda put that on the label. tucker: they had done no studies customer they had no long-term studies on whether it would mean less addiction down . there were like road bump. 2007, purdue had to plead guilty to felony misbranding, misrepresenting the drug as not addict
so one of the sorriest parts of the story on the drug industry in general, but the story part in particular on opioids is the fda. and it s not that they are complicit in terms of sitting there and taking a bundle of money over the table and saying okay, we are going to do this. they just weren t very effective regulators. and that comes from approved oxycontin. in other words, purdue went to them and said we would like a couple of things on the label. we would like on the label that the odds of addiction are very rare because this is a time release formula. and we believe that the study show that there is something to that. the fda had no studies. there was no proof of that. purdue had done no studies of that but the fda put that on the label. tucker: they had done no studies? they had no long-term studies on whether it would mean less addiction down the road.bebe s there were like road bump.
Mi padre está en un refugio : el tenso momento que enmudeció a Eduardo Feinmann y a todo el estudio ESPECTÁCULO El Intransigente elintransigente.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elintransigente.com Daily Mail and Mail on Sunday newspapers.